FI3972603T3 - Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää - Google Patents

Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää Download PDF

Info

Publication number
FI3972603T3
FI3972603T3 FIEP20729203.8T FI20729203T FI3972603T3 FI 3972603 T3 FI3972603 T3 FI 3972603T3 FI 20729203 T FI20729203 T FI 20729203T FI 3972603 T3 FI3972603 T3 FI 3972603T3
Authority
FI
Finland
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
FIEP20729203.8T
Other languages
English (en)
Finnish (fi)
Inventor
Souvik Bhattacharya
Bruno Bieth
Maciej Cabanski
Bruno Cenni
Buck Stefan De
Martin Kaul
Arvind Kinhikar
Andrijana Radivojevic
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3972603T3 publication Critical patent/FI3972603T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP20729203.8T 2019-05-23 2020-05-20 Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää FI3972603T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
FI3972603T3 true FI3972603T3 (fi) 2024-12-04

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20729203.8T FI3972603T3 (fi) 2019-05-23 2020-05-20 Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää

Country Status (23)

Country Link
US (2) US12383556B2 (https=)
EP (2) EP3972603B1 (https=)
JP (2) JP7765970B2 (https=)
KR (1) KR20220011652A (https=)
CN (1) CN113811301A (https=)
AU (2) AU2020278236C1 (https=)
BR (1) BR112021023110A2 (https=)
CA (1) CA3137271A1 (https=)
CL (1) CL2021003034A1 (https=)
DK (1) DK3972603T3 (https=)
ES (1) ES3004516T3 (https=)
FI (1) FI3972603T3 (https=)
HR (1) HRP20241584T1 (https=)
HU (1) HUE069020T2 (https=)
IL (1) IL287745B2 (https=)
LT (1) LT3972603T (https=)
MX (1) MX2021014161A (https=)
PL (1) PL3972603T3 (https=)
PT (1) PT3972603T (https=)
RS (1) RS66195B1 (https=)
SI (1) SI3972603T1 (https=)
TW (1) TWI857060B (https=)
WO (1) WO2020234781A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MX2023008671A (es) * 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
CN116782888A (zh) * 2021-01-26 2023-09-19 诺华股份有限公司 药物组合物
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102875105B1 (ko) 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532310A (en) 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
LT3390390T (lt) 2015-12-16 2021-11-25 Boehringer Ingelheim International Gmbh Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
US10874741B2 (en) 2017-08-28 2020-12-29 Spectrix Therapeutics, LLC Compound to treat Sjogren's syndrome
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Also Published As

Publication number Publication date
IL287745B1 (en) 2025-10-01
JP2025165957A (ja) 2025-11-05
IL287745B2 (en) 2026-02-01
TWI857060B (zh) 2024-10-01
EP3972603B1 (en) 2024-09-04
EP4442321A2 (en) 2024-10-09
AU2020278236A8 (en) 2022-04-28
AU2025263830A1 (en) 2025-11-27
US12383556B2 (en) 2025-08-12
ES3004516T3 (en) 2025-03-12
CN113811301A (zh) 2021-12-17
EP3972603A1 (en) 2022-03-30
EP4442321A3 (en) 2025-01-01
AU2020278236C1 (en) 2026-02-26
AU2020278236B2 (en) 2025-08-07
RS66195B1 (sr) 2024-12-31
TW202110451A (zh) 2021-03-16
DK3972603T3 (da) 2024-12-02
US20220175772A1 (en) 2022-06-09
WO2020234781A1 (en) 2020-11-26
JP7765970B2 (ja) 2025-11-07
BR112021023110A2 (pt) 2022-04-12
LT3972603T (lt) 2024-12-10
PL3972603T3 (pl) 2025-02-03
CL2021003034A1 (es) 2022-09-09
PT3972603T (pt) 2024-11-26
US20250339428A1 (en) 2025-11-06
SI3972603T1 (sl) 2025-02-28
HRP20241584T1 (hr) 2025-01-31
HUE069020T2 (hu) 2025-02-28
JP2022533968A (ja) 2022-07-27
MX2021014161A (es) 2022-01-04
KR20220011652A (ko) 2022-01-28
AU2020278236A1 (en) 2022-01-06
CA3137271A1 (en) 2020-11-26
IL287745A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
FI3972603T3 (fi) Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää
IL324294A (en) Aryl-or heteroaryl-substituted benzene compounds
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
DE59610077D1 (de) Phenyldihydrobenzofurane
ATE318589T1 (de) Carbocyclische hydrazino-hemmer von kupferhaltigen aminoxidasen
EP0729355A4 (en) Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
Peters et al. L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
RU2008140117A (ru) МОНОМЕР TGF-β И ЕГО ПРИМЕНЕНИЕ
DE59610031D1 (de) Cyclohexyldihydrobenzofurane
MX2025002705A (es) Isoquinolonas como inhibidores de pi3k
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
EP1539714A4 (en) 8-HYDROXY-1-OXOTETRAHYDROPYRROLOPYRAZIN COMPOUNDS SUITABLE AS INHIBITORS OF HIV INTEGRASE
Wach et al. Treatment of severe localized scleroderma by plasmapheresis report of three cases
RU2008143055A (ru) Ингибиторы ренина, предназначенные для гипертензии
RU2024121617A (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
CN111065389A (zh) 治疗自身免疫性微脉管疾病的方法
RU2021138149A (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
WO2007145993A3 (en) Modified compositions and methods for enhancing brain function
PT1259229E (pt) Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil